Novel novel anti-tuberculosis (TB) agent, possessing improved safety properties compared to bedaquiline

Cell permeable Cx43 hemichannel blocker, being used a control peptide for TAT-Gap19

Negative control for T3-CLK

Prodrug of ADAM17 inhibitor SN-4

Negative control for SGC-STK17B-1, showing IC50 > 10,000 nM against STK17B

Negative control for SGC-CLK-1

Negative control for SGC-CK2-1

Negative control for SGC-CAMKK2-1

Negative control for SGC-SMARCA-BRDVIII

Novel cell permeable CD45 phosphatase inhibitor; Prodrug of RWJ-60475

Metabolite of ozanimod, exhibiting a similar specificity profile as ozanimod at the S1P receptor family in vitro and pharmacodynamic profile in vivo

Negative control for Borussertib, being >1000 fold less potent in vitro than Borussertib

Clickable Remodelin analog

Prodrug of RO5203548, a selective agonist of the trace amine-associated receptor 1 (TAAR1)

Novel Orally Bioavailable Prodrug of Boronic Acid β-Lactamase Inhibitor QPX7728

An isomer of PU-H54, a novel Grp94- and Hsp90-selective inhibitor

Prodrug of DMOCPTL

Negative control for Primordazine A and Primordazine B

Negative control for PPTN

Less active enantiomer of LGH447, acting as a selective weak pan-PIM inhibitor (IC 50 (µM): PIM1 0.095; PIM2 0.522; PIM3 0.369) in comparision with LGH447 (IC 50 (µM): PIM1 0.001; PIM2 0.002; PIM3 0.002)

Deuterated internal standard for PhIP

Negative control for PFI-6

Negative control for PFI-653

Metabolite of PF-04691502, a highly potent and selective ATP competitive kinase inhibitor of class 1 PI3Ks and mTOR

Pro-drug of furamidine, acting as antiprotozoal/antifungal agent

Novel PA-9 analog, acting as an antagonist of the PAC1 receptor, showing improved antagonistic activities than PA-9

Prodrug of antitumor agent oncrasin-72, with improved stability, pharmacokinetics, and safety

Novel potent and highly selective KDM1A chemoprobe, exhibiting a selectivity profile similar to the parent compound ORY-1001

PET Precursor of VU0467485

Negative control for NVS-MLLT-1